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Abstract
Hepatocellular carcinoma (HCC) is a multistep heterogeneous disease as it is related to the 
risk factors such as HBV and HCV infections, including uncontrolled hepatocyte prolifera-
tion, invasion of the neighboring tissue and metastasize to distant tissues. There are sev-
eral factors affecting the course of HCC among the patients such as oncogenes and tumor 
suppressor genes. Recently, molecular mechanisms have cleared some of the underlying 
mechanisms of carcinogenesis, especially the microRNAs, the upstream regulators of a 
large number of critical genes. Mature miRNAs found to be mounted into RISC, which 
helps in recognizing the complementary binding sites in the 3′ untranslated regions of tar-
get genes. That binding causes the degradation of/or inhibition of translation of mRNAs. 
miRNAs have been reported to be deregulated in human cancers demonstrating their dou-
ble-edged role as a tumor suppressor and as an oncogene. miRNA deregulation is involved 
in modulating signal pathways of cellular transformation of a normal cell into a cancer cell. 
miRNAs have been reported to be associated with the processes of carcinogenesis includ-
ing inflammation, cell-cycle, differentiation, apoptosis, and metastasis. miRNAs have been 
considered as potential biomarkers in HCC as their development has been attributed to the 
deregulation of many genes owing to abnormal expression of miRNAs. Herein, the current 
chapter will focus on studying the regulation of miRNAs in HCC-related HCV patients.
Keywords: miRNA, HCC, HCV, UTR, fibrosis progression
1. Introduction
MicroRNA (miRNA) has been proven as key regulator homeostasis for multiple biological 
systems, besides modulation of the disease pathology of many cancers. Experimental target 
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miRNA biogenesis as key regulators using small molecules or other interferences sheds light 
on its crucial role in regulating posttranscriptional gene expression. Further studies reported 
the variability of their loci, the genetic organization, and their tissue specificity, besides con-
trolling the translation of target protein and transcriptome in response to physiologic envi-
ronmental cues, along with their vulnerability to become designated in diseases like cancer 
and fibrosis, including that related to infection viruses like HCV. Many pathways analysis 
of targeted genes performed using infection-associated miRNAs showed that the pathways 
related to signal transduction activation, DNA damage, and cell death were clearly observed 
in HBV-infected liver, while proteasome, lipid metabolism activation, immune response, 
and antigen presentation were predominantly in HCV-infected liver. These differences are 
associated with miRNAs’ level in the infected liver and it was confirmed in cell line like 
Huh7.5 cells in which infectious HBV or HCV clones can be replicated, which proved that 
miRNAs act as key mediators of HCV and HBV infection and liver disease progression as 
well; therefore, miRNAs can act as liable therapeutic target molecules in the field of transla-
tional medicine.
2. Tissue-specific expression and variation level of miRNAs
MicroRNAs are a class of small, endogenous, conserved, non-coding RNAs with a length of 
20–24 ribonucleotide RNA sequence that is biosynthesized through transcription of miRNA 
genes into primary transcripts (pri-miRNA), which are processed by the drosha, generat-
ing a precursor of a length of 70 nucleotides (pre-miRNA) with a hairpin-like structure. A 
remarkable mechanistic difference in canonical against noncanonical miRNAs is that canon-
ical is drosha-dependent intronic miRNAs and so treated co-transcriptionally in the nucleus 
with protein-coding transcripts. Pre-miRNA is then processed by dicer in the cytoplasm 
generating mature miRNA duplexes. Mature miRNAs are then mounted into RISC (an 
miRNA-induced silencing complex) which helps in recognizing the complementary bind-
ing sites in the 3′UTR of target genes. Noncanonical intronic, ones called mirtrons, originate 
from small introns that are similar to pre-miRNAs and can detour the drosha-processing 
step [1, 2]. Noncanonical pathway affects common cellular response pathways like prolifera-
tion and apoptosis by targeting various mRNA transcripts [1]. miRNA binding causes the 
degradation of, or inhibition of, translation of mRNAs. miRNAs have been reported to be 
deregulated in human cancers demonstrating their double-edged role as a tumor suppressor 
and as an oncogene that offers miR clusters as complex and adaptive regulatory controllers 
for disease progression. Comparative research assessing the organizational structure for the 
mammalian genome has noticed enrichment in one of the following: copy number varia-
tion, chromosomal deletion or insertion, and single nucleotide polymorphisms (SNPs) that 
subsidize phenotypic diversity. This diversity is obvious in all aspects of human health and 
investigated diseases. No wonder there is a mounting gratitude to the variation in miRNAs 
and their target genes in phenotypic variability. Numerous solid malignancies that included 
hepatocellular carcinoma (HCC) proved to be correlated with miRNAs located at deleted, 
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amplified, or translocated chromosomal regions [3]. Variation in gene expression or regu-
lation affected by expression of the quantitative trait loci is caused due to genetic variants 
in either cis- or trans-acting SNPs [4]. A remarkable criterion of miRNA binding is their 
capability to distinguish binding site polymorphism (miRSNPs) in transcribed functional 
genes, as in the case of miR 214-5p that appears to be dysregulated in HCC [2] and miR-
24 in the case of colorectal tumor by the targeting site of polymorphism in the dihydrofolate 
reductase gene [5]. This binding causes inhibition of translation for its transcripts and can 
phenocopy the phenotypic character of such a disease with genetic knockouts of the respon-
sible gene [5].
Screening miRNA genetic variation and differential expression level across the human pop-
ulation in healthy and disease patients provides more insights on variable causes of disease 
progression and susceptibility in addition to physical functionalities [4]. Comparative genomic 
studies showed that the untranslated regions (UTRs) within the mRNA sequence act as a target 
sequence even for mRNA-UTR-displaying variants; during miRNA-mRNA adaptive coevolu-
tion, the co-expressed miRNA selects its cognate UTR mRNA, which depends on whether the 
dysregulation of protein output will be harmful, beneficial or inconsequential for the desired 
effect [6].
Evaluating reports on tissue-specific differential expression of miRNAs showed the cross-
regulation feature of miRNAs and its correlation to stability of phenotype differentiation 
[7], as an example, regulation of neurite outgrowth, dendritic spine size, and neural dif-
ferentiation that is regulated by overexpression of miR219, miR134, miR128, miR24, miR7, 
and others [7]. In the same strategy, miR499, miR486, miR208, miR206, miR133, and miR1 
proved to control skeletal muscle growth, maintenance and differentiation [8], while 
miR133 proved to inhibit osteogenic cell-linage differentiation through controlling Runx2 
that is required for bone development, differentiation, and formation. Not only the previ-
ously mentioned roles but miRNAs can also exert specialized functions as in case of hypo-
thalamus; fine-tuning expression of oxytocin; and Fos controlled by hyper-expression of 
both miR24 and miR7 and hence they control lactation and parturition through controlling 
water in the body [9].
MicroRNA (miRNA) has been proven as key regulator homeostasis for multiple biological 
systems, besides modulation of the disease pathology of many cancers. Experimental target 
miRNA biogenesis key regulators using small molecules or other interferences sheds light 
on its crucial role in regulating posttranscriptional gene expression. Further studies reported 
the variability of their loci, the genetic organization, and their tissue specificity [10], besides 
controlling the translation of target protein and transcriptome in response to physiologic 
environmental cues, along with their vulnerability to become designated in diseases like can-
cer and fibrosis, including that related to infection viruses like HCV. Many pathways analysis 
of targeted genes performed using infection-associated miRNAs showed that the pathways 
related to signal transduction activation, DNA damage, and cell death are clearly observed 
in HBV-infected liver, while proteasome, lipid metabolism activation, immune response, and 
antigen presentation were predominantly in HCV-infected liver [2, 3]. These differences are 
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associated with miRNAs’ level in the infected liver and it was confirmed in cell line like 
Huh7.5 cells in which infectious HBV or HCV clones can be replicated, which proved that 
miRNAs act as key mediators of HCV and HBV infection and liver disease progression as 
well; therefore, miRNA can act as liable therapeutic target molecules in the field of transla-
tional medicine [11].
Since miRNA discovery as a liable promising class of small non-coding RNAs able to regulate 
protein translation and stability of mRNA, miRNAs have been implicated as key regulators in 
many diseases like cancer and autoimmune disease. So there is great effort to leverage knowl-
edge of the miRNA regulatory system to these diseases, especially cancer [12].
3. MicroRNAs and disease susceptibility
Development in the pathobiology of miR Nas sheds light on its crucial character in transcrip-
tome modulation which can reflect cancer state in addition to its application in attenuating 
possible risks that may be raised during cancer progression [13]. Currently, there is no doubt 
that down-regulating epithelial markers causes disruption in epithelial mesenchymal that is 
directly associated with differentiation of epithelial cells in lung cancer, a key developmental 
pathway in lung cancer progression and metastasis [14]. So expression of miRNA can be used 
as a progression marker for cancer disease depending on its differential expression during 
invasion, progression, and metastasis of cancer [3].
Reduction in dicer expression is often noticed in cancer stem cells like muscle stem cell tumors 
and rhabdomyosarcoma in periodic cases, shown to be correlated with the down-regulated 
level of myomiRNAs like miR 133 and miR 1 [15]. OncomiRNAs is a type of miRNA that can 
decrease tumor suppressor gene expression which leads to phenotype attenuation or promo-
tion for oncogenic characters; miR92, miR21, and niR17 are members of that family that can 
modulate cell-cycle regulators like P21, PTEN, and E2F that can promote tumor proliferation 
[3, 12]. On the other hand, tumor-suppressor miRNAs, like let-7, target directly mRNA for 
silencing [3]; over-expressed Let7 has proved to modulate cell-cycle regulators that lead to 
tumor invasion and metastasis. So these miRNAs can be used as prognostic tools for can-
cer incidence or as a parameter for treatment susceptibility. In squamous cell carcinoma and 
adenocarcinoma, a comparative miRNA expression profiling revealed a significant difference 
that reached a specific signature to predict overall survival between male smoker patients in 
addition to the study performed by Liu et al. that clearly declared correlation between overall 
pathobiology in cancer and tissue-context miRNA expression [15]. Our team recently proved 
a small panel of four miRNAs that can act as a liable prognostic marker for HCC progression 
besides its ability to discriminate different stages in hepatocellular carcinoma [2].
3.1. miRNAs and hepatic diseases
Studies for understanding miRNAs in liver diseases showed a significant progression in 
that field, making liver a promising first organ to achieve precision and targeted therapy. 
Depending on accumulated studies of miRNA in liver disease, the unique vasculature of the 
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liver, and the efficiently rapid accumulation of exogenous small RNAs, the liver showed a 
good target for RNAi targeted therapy. Manipulation of miRNAs in liver diseases proved 
great evidences in that field; as an example miR122 clearly illustrates a good effective target 
for ameliorating hepatic steatosis besides many studies that showed miR122 to be a good 
target in HCV targeted therapy through its role in production of neutralizing antagomirs. 
MicroRNAs as a key target for viral hepatitis afford another liable possibility for targeting 
HBV and HCV infection that, by one way or another, causes HCC progression and death upon 
chronic infection; this targeting prevention will help to reduce HCC risk incidence by regulat-
ing many oncogenic miRNAs like miR222, miR221, and miR21 or via tumor suppression ones 
like miR199 and miR122 that nowadays are used as liable biomarkers in HCC, besides many 
promising studies that showed its role as prognostic and a marker for therapy response.
3.1.1. miRNA as a metabolic modulator in hepatic diseases
Non-alcoholic fatty liver diseases (NAFLD) are characterized by increased liver fat content 
and progression to liver inflammation, fibrosis, and ultimately cancer [16, 17]. Obesity, insu-
lin resistance, and diabetes mellitus are risk factors for this disease and it is estimated that 
NAFLD will be the most common problem in internal medicine by 2020 [18]. Despite the high 
prevalence of NAFLD, the biology behind the disease progression is not clear and impor-
tantly there is no specific treatment for this condition, so osculating necessity for liable bio-
markers and discovery of potential drug targets, as researched by Benhamouche-Trouillet 
et al., showed that miR-21 may be implicated at various steps during the NAFLD disease 
progression in a cell-specific manner through modulation of PPARα [19]. Specific conditional 
dicer1 deletion from embryonic liver leads to disruption in maturation of microRNA from its 
pre-microRNA form which leads to striking of metabolic phenotypes that include steatosis 
together with triglyceride and fatty acid accumulation in addition to dysregulation of blood 
glucose in fasting mice under study [12]. On the other hand, miR-355 has been recently con-
sidered as a liable biomarker for hepatic lipid accumulation in rat experiments as its elevated 
level strongly correlated with obesity in mice in association with liver steatosis [15]; for that 
reason, a high-throughput screen for miRNAs as a predictor for lipid droplet formation in the 
liver metabolic disorder in humans is a great demand for disease progression, overall survival 
rate, and even for prognosis of possible hepatic disorder (as shown in Figure 1 and Table 1).
The conflicting concerns about whether profile expression of miRNA correlated with NASH 
or NAFLD have also been well investigated. Sanyal [20] research group reported in double 
subject groups, including NASH and metabolic syndrome group, in addition to the control 
group; control groups were matched in BMI. His investigators reported 23 up-regulated miR-
NAs and the same number of down-regulated miRNAs, with detailed interpretation referring 
to the role of some miRNA expression dysregulation, that is, miR-34a and miR-146b up- 
regulation besides miR-122 down-regulation in NASH subjects. Odd findings were reported 
in human subjects with NASH-like decreased expression of miR-122. However, the protective 
feature arise from silencing of miR-122 specially in high fat-fed mice bears only indirect physi-
ological matter differentiate steady-state cross-sectional investigations in overweight or obese 
humans subjects with such a fatty liver disease. This result includes the complexity of dissect-
ing effects and causes cross-talk in hepatic expression of miR-122 and metabolic liver disease.
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Liver diseases Down-regulated miRNAs Up-regulated miRNAs Dysregulated miRNA
Steatohepatitis miR-21 miR-17 miR-21
miR-29a miR-24 miR-33a/b
miR-130a miR-27 miR-122
miR-185 miR-34a miR-155
miR-205 miR-103
miR-206 miR-107
miR-378 miR-122
miR-451
The importance of miRNAs cross-talk analysis was further elucidated in many publications 
where hepatic steatosis variations was evolved through application of an adenovirus encod-
ing a dominant negative c-Jun and then testing changes in miRNA expression that is associ-
ated with it [21]. They found many miRNAs (miR-122 and miR-370 was common among 
many publications) to be differentially expressed (DE) in liver tissues of mice that were 
treated by adenovirus and showed that the elevated presence of miR-370 correlated with the 
osculating expression of hepatic lipogenic target mRNAs (e.g., FAS, SREBP-1c, and DGAT2); 
these findings suggest that dietary modulation of some miRNA expression is a relevant con-
sideration [21].
Figure 1. miRNA that either up-regulated or down-regulated with its target genes in different stages of HCC disease 
progression.
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Liver diseases Down-regulated miRNAs Up-regulated miRNAs Dysregulated miRNA
HCV infection Let-7 miR-21 miR-126
miR-17 miR-122 miR-192
miR-27a miR-141 miR-198
miR-29a,b,c miR-146a miR-345
miR-130a miR-192
miR-155 miR-215
miR-181a miR-491
miR-194
miR-196
miR-199a
miR-221
HCC Let-7 miR-18a miR-233
miR-1 miR-21
miR-15a miR-92a
miR-16 miR-130b
miR-26a miR-141
miR-29 miR-155
miR-34a miR-181
miR-101 miR-195
miR-122 miR-221
miR-124 miR-222
miR-125b miR-224
miR-126 miR-494
miR-138 miR-1269
miR-141
miR-145
miR-146a
miR-148
miR-195
miR-199
miR-200
miR-223
miR-375
Table 1. Liver diseases in association with the microRNA level in each stage.
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3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the enzyme that catalyzes mevalonic 
acid synthesis rate-limiting step in cholesterol and other isoprenoid production, showed both 
miR-21 and miR-34a as key player molecules in this step, through controlling dephosphoryla-
tion and activation of HMGCR [22]. One requirement for any effort to enhance miRNA levels 
as therapeutic tools is the well-established pro-oncogeneic characters for miRNAa in HCC 
and its related diseases, which will be discussed later here.
3.1.2. miRNA and HCV infection susceptibility
Hepatitis C virus is the sole member of hepacivirus C species that is known to be a blood-
borne infectious viral disease causing the significant persistence of liver disease, with around 
110–170 million infected patients globally, with nearly two-thirds of this number chronically 
infected and not less than one-third developing fibrosis and cirrhosis after 20 years of the 
onset of infection; most of them develop different stages of hepatocellular carcinoma [23]. 
Possible therapy for chronic hepatitis C (CHC) virus treatment has undergone a great trans-
formation recently; discoveries in viral infections in humans have shown surprising findings 
that have broadened our understanding of miRNA function within human body.
In the setting of the HCV infection, the role of various miRNAs in modulating the viral infection 
response has been deeply studied, that clarifies causes of chronic hepatitis C progression in most 
infected patients and consequences of infection with its manipulation in the risk of develop-
ing cirrhosis and HCC [24]. The HCV virus is a positive-sense, single-stranded RNA virus of 
9600 base [25]. It contains 5′ untranslated region (UTR) that contains four structurally conserved 
domains besides an internal ribosomal entry site (IRES) which allows viral RNA translation 
in a cap-independent manner with minimal dependence on canonical translation factors [26]. 
Translation of viral RNA leads to a polyprotein product that consists of six nonstructural and 
four structural viral proteins that undergo additional proteolysis by viral and host enzymes [27].
Subgenomic systems are easier to proceed after discovery of first sustainable cell-culture 
models for hepatitis viruses, in 1999 [28]. A noticed curious aspect in these early sustainable 
replicon systems was the successful sustainability of viral replication in Huh7 cell line but not 
HepG2, albeit both of these transformed cell lines have their origin in hepatocellular cancer in 
humans. The biologic declaration for this conflicted efficiency was first explained by Jopling 
et al. in 2005. When he verified that miR-122 has a detectable level in Huh7 but not HepG2 
[29], in addition to that, he recently noticed that HCV contains a recognition site for the miR-
122’s seed sequence in the UTR area of viral genome. The miR-122-interacted viral elements 
have been mapped to two conserved points within 5′ UTR among stem-loop I and/or II, cor-
responding to the seed sequence of the miR-122 [30]. The finding was more astounding on the 
grounds that it appeared to be illogical to the customary thought of RNAi as an innate antivi-
ral response like in invertebrates or plants [31]. Inhibition of RISC effector complex molecules 
like drosha, dicer1, DGCR8, and the RISC using small interfering RNA (siRNA) appears to 
inhibit HCV replication [32]. Although the mechanism underlying the miR-122 interaction 
with HCV is not precisely understood, miR-122 binding site position within the 5′ UTR 
proved to be critical, so translocation of this site to the 3′ UTR in a luciferase reporter mRNA 
causes up-regulation in reporter activity upon miR-122 diminished levels [30]. MiR-122 has 
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been assumed to elevate both replication and translation of RNA, independently from viral 
replication [33]. Up-regulation of the translation step through miR122 dependent pathway 
is observed in reporter and full-length HCV genome constructs [34]. Also, Jangra et al. [35] 
deliberated the mutations of full-length HCV constructs that are capable of generating infec-
tious virions in vitro. He found zero overlapped mutations within the miRNA or IRES bind-
ing site in distinct constructs. In those harboring mutations in IRES, infective viral production 
was down-regulated by more than 28-fold in comparison with constructs with the miR-122 
binding site disruption that showed more than a 3000-fold reduction [35]. These observations 
are important in description of the role of miR-122 in HCV infection that requires searching 
beyond HCV replication, translation, and stability to investigate more pathways like liable 
RNA targets in HCV biology or posttranslational targets for it, as an example, heme oxygen-
ase-1 (HO-1) which catalyzes the degradation of heme to biliverdin. Oxidative stress causes 
HO-1 elevation. Incubation of HCV-infected cell lines with biliverdin causes reduction in 
HCV amplicons via stimulation of interferon pathways [36]. Heterodimers of BACH1 and 
a member of the Maf protein family cause transcription repression of HO-1. It was observed 
that BACH1 3′ UTR contains miR-122 binding sites; its function was confirmed to be impor-
tant by silencing miR-122 that leads to increased HO-1 mRNA levels double fold. Not only 
that but BATCH1 silencing using siRNA or other chemical means like heme or cobalt proto-
porphyrin also decreased HCV RNA level [37].
However, in these research-based findings, miR-122 proved to be essential in replication 
of HCV. Later cloned HCV from other genotypes proved to be replicated in some cell lines 
like HepG2 cells [38], liver cells (hepa1–6) [39], and cervical cancer-derived HeLa cell from 
humans [40]. In addition, the findings from cell culture are not yet completely correlated with 
outcomes from clinical infection, like miR-122 level in liver tissue of infected patients and viral 
load [41]. Moreover, HCV therapy non-responder (NR) patients showed lower pretreatment 
miR-122 levels in liver tissue biopsies rather than responders [41]. Another study showed 
inverse correlation between severity of hepatic fibrosis and hepatic miR-122 expression levels 
[42]. Even bearing in mind those conclusions, there is still convincing evidence that miR-
122 targeted therapy may act as a liable strategy in HCV precision medicine. For example, 
Lanford et al. treated chronically infected chimpanzees with an LNA-modified oligonucle-
otide against miR-122 [43]. There was a significant drop by 2.6 orders of magnitude of HCV in 
the chimpanzee that received the optimal dose of this agent besides significant improvement 
in histologic examination of the liver specimens. Additionally, 5′ UTR sequencing indicated 
no signs for selection of adaptive mutations to the recognition site of miR-122. Similar find-
ings were also reported in human clinical trials, phase II, that test the LNA-modified phos-
phorothioate antisense DNA oligonucleotide and the anti-miR-122 antagomir (Miravirsen) 
[44]. These findings were so encouraging to researchers, where the Miravirsen subcutaneous 
injection reduces serum HCV viral load in a dose-dependent manner, up to a 3-log reduction 
over 2–5 months [44]. Small molecules synthesis that targets miR-122 raises the possibility for 
new opportunities in HCV infection treatment [45].
However, miR-122 is the finest studied HCV-related miRNAs; it is not sole. There are 
others like MiR-199a that recognize HCV 5′ UTR and so suppress viral load [46]. Also, 
MiR196 down-regulates BACH1 [47], and MiR-196 is up-regulated in response to interferon 
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signaling [48]. Besides, immune-regulatory miRNA-155 is induced by antiviral TLR3/4 sig-
nals [49]. Elevated MiR-155 levels in HCV-infected patients appeared to be inversely pro-
portional to serum viral loads, signifying its relevant antiviral effect through suppression of 
Tim-3 (HAVCR2) that acts as an immune signaling modulator that is elevated in NK cells 
of HCV-infected patients where its up-regulation leads to inhibition of Tim-3 that causes 
an escalating production of interferon-γ (IFNγ) [50]. Not only that but MiR-155 also shows 
antiviral effects against other viruses like HIV infection through TLR3/TLR4 signaling path-
way that prevents macrophage infection by HIV. Last but not least, miR-21, like many miR-
NAs, is induced by HCV infection but its induction aids HCV and escapes the immune 
response through directly suppressing interleukin-1 receptor-associated kinase 1 (IRAK1) 
and myeloid differentiation factor 88 (MyD88) [51] that is mandatory for mediating induced 
interferon response (type I) upon HCV infection. So, augmentation of miRNA expression 
levels and activity may prove a valuable aspect in HCV treatment and probably other viral 
infections.
4. MicroRNA inhibitors as a promising therapeutic approach
From the therapeutic point of view, silencing some miRNAs that encode potential vital or 
good protein-coding genes that is mandatory to preserve our health status. Inhibitors for 
these miRNAs have been considered for prospective therapeutic agents. Several approaches 
include direct delivery of miRNA-ASO or expressing it via mini-circle or viral vectors, which 
have been recognized for effective miRNA knockdown in vitro and in vivo too. Lately, miR-
ASO-based therapy has been applied in humans and promising ongoing clinical trials consid-
ering liver sicknesses [52].
5. Conclusions
In conclusion, miRNA is a vital feature of assurance and monitoring throughout the tissue 
growth and disease states. In the near term, there will be much to be learned about adaptive 
or maladaptive states by an investigative way of differential expression of many miRNAs 
that is affected by the miRNA genetic architecture, mirtrons, and clusters in addition to SNP 
in miRNA or polymorphism in their target mRNA. There are diverse approaches of miRNA 
regulatory mechanism of action, for example negative, positive feedback and cross-regulatory 
through which various biological processes can be monitored, modulated or even resolved its 
signaling pathways, include fibrosis, viral infection and cancer. Possibly the micromanage-
ment and homeostasis of these systems of regulatory miRNAs, when disturbed, can attain 
novel wannabe steady state of interacted interfaces that show an undesired effect in disease 
progression and severity especially in viral-related cancer cases like HCC. So, an enhanced 
sympathetic of these miRNA regulatory networks, in addition to improved therapeutic tools 
for controlling miRNA expression or their targets toward healthy regulatory states, will gain 
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more interest over the coming years. Indeed, modern advanced miRNA precision-based med-
icine will undergo advanced phases of clinical trials that will afford more understandings 
into the biosafety and bioavailability in addition to the efficacy of miRNA as therapy and 
diagnostic tools.
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HO-1 heme oxygenase-1
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LNA locked nucleic acid
miR micro-ribonucleic acid
NAFLD non-alcoholic fatty liver diseases
NASH non-alcoholic steatohepatitis
PTEN phosphatase and tensin homolog
RISC RNA-induced silencing complex
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Micro-RNA in Hepatocellular Carcinoma - Related Hepatitis C Virus Patients in Correlation…
http://dx.doi.org/10.5772/intechopen.76209
97
Notes/Thanks/Other declarations
I would like to thank Mrs. Yasmin Ibrahim Hamed for her support while writing and editing 
this work.
Author details
Moustafa Nouh Elemeery1,2,3*
*Address all correspondence to: mn.badr@nrc.sci.eg
1 Center for Systemic Biotechnology, Korea Institute of Science and Technology, 
Gangneung, Gwang-do, Republic of Korea
2 Division of Biomedical Science and Technology, Korea University of Science and 
Technology, Daejeon, Republic of Korea
3 Microbial Biotechnology Department, Genetic Engineering and Biotechnology Research 
Division, National Research Centre, Dokki-Giza, Egypt
References
[1] Dai R, Ahmed SA. MicroRNA, a new paradigm for understanding immunoregulation, 
inflammation, and autoimmune diseases. Translational Research. 2011;157(4):163-179
[2] Elemeery MN et al. Validation of a serum microRNA panel as biomarkers for early diag-
nosis of hepatocellular carcinoma post-hepatitis C infection in Egyptian patients. World 
Journal of Gastroenterology. 2017;23(21):3864
[3] Nana-Sinkam SP, Croce CM. MicroRNAs as therapeutic targets in cancer. Translational 
Research. 2011;157(4):216-225
[4] Zhou T, Garcia JG, Zhang W. Integrating microRNAs into a system biology approach to 
acute lung injury. Translational Research. 2011;157(4):180-190
[5] Clop A et al. A mutation creating a potential illegitimate microRNA target site in the 
myostatin gene affects muscularity in sheep. Nature Genetics. 2006;38(7):813
[6] Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell. 2009;136(2): 
215-233
[7] Lian JB et al. MicroRNA control of bone formation and homeostasis. Nature Reviews 
Endocrinology. 2012;8(4):212
[8] Townley-Tilson WD, Callis TE, Wang D. MicroRNAs 1, 133, and 206: Critical factors 
of skeletal and cardiac muscle development, function, and disease. The International 
Journal of Biochemistry & Cell Biology. 2010;42(8):1252-1255
Hepatitis C - From Infection to Cure98
[9] Meister B, Herzer S, Silahtaroglu A. MicroRNAs in the hypothalamus. Neuroendocrinology. 
2013;98(4):243-253
[10] Ryan DG, Oliveira-Fernandes M, Lavker RM. MicroRNAs of the mammalian eye dis-
play distinct and overlapping tissue specificity. Molecular Vision. 2006;12(134):I175-I184
[11] Ura S et al. Differential microRNA expression between hepatitis B and hepatitis C lead-
ing disease progression to hepatocellular carcinoma. Hepatology. 2009;49(4):1098-1112
[12] Laurence J. Translating MicroRNAs to the Clinic. London, United Kingdom: Academic 
Press; 2016
[13] Aoi W, Sakuma K. Does regulation of skeletal muscle function involve circulating 
microRNAs? Frontiers in Physiology. 2014;5:39
[14] Cortez MA et al. MicroRNAs in body fluids—The mix of hormones and biomarkers. 
Nature Reviews. Clinical Oncology. 2011;8(8):467
[15] Liu X et al. Involvement of microRNAs in lung cancer biology and therapy. Translational 
Research. 2011;157(4):200-208
[16] Kleiner DE et al. Design and validation of a histological scoring system for nonalcoholic 
fatty liver disease. Hepatology. 2005;41(6):1313-1321
[17] Day CP. From fat to inflammation. Gastroenterology. 2006;130(1):207-210
[18] Guerrero R et al. Ethnic differences in hepatic steatosis: An insulin resistance paradox? 
Hepatology. 2009;49(3):791-801
[19] Benhamouche-Trouillet S, Postic C. Emerging role of miR-21 in non-alcoholic fatty liver 
disease. Gut. 2016;65:1781-1783. gutjnl-2015-310044
[20] Sanyal AJ et al. Nonalcoholic steatohepatitis: Association of insulin resistance and mito-
chondrial abnormalities. Gastroenterology. 2001;120(5):1183-1192
[21] Iliopoulos D et al. MicroRNA-370 controls the expression of microRNA-122 and Cpt1α 
and affects lipid metabolism. Journal of Lipid Research. 2010;51(6):1513-1523
[22] Min H-K et al. Increased hepatic synthesis and dysregulation of cholesterol metabo-
lism is associated with the severity of nonalcoholic fatty liver disease. Cell Metabolism. 
2012;15(5):665-674
[23] Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and 
HCV-related disease. Nature Reviews. Gastroenterology & Hepatology. 2017;14(2):122
[24] Cazanave SC et al. A role for miR-296 in the regulation of lipoapoptosis by targeting 
PUMA. Journal of Lipid Research. 2011;52(8):1517-1525
[25] Miller AM et al. MiR-155 has a protective role in the development of non-alcoholic hepa-
tosteatosis in mice. PLoS One. 2013;8(8):e72324
[26] Sharma H et al. Expression of genes for microRNA-processing enzymes is altered in 
advanced non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology. 
2013;28(8):1410-1415
Micro-RNA in Hepatocellular Carcinoma - Related Hepatitis C Virus Patients in Correlation…
http://dx.doi.org/10.5772/intechopen.76209
99
[27] Alter MJ et al. Risk factors for acute non-A, non-B hepatitis in the United States and asso-
ciation with hepatitis C virus infection. Journal of the American Medical Association. 
1990;264(17):2231-2235
[28] Wree A et al. Obesity affects the liver—The link between adipocytes and hepatocytes. 
Digestion. 2011;83(1-2):124-133
[29] Yamada H et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-
122 and miR-451) and non-alcoholic fatty liver. Clinica Chimica Acta. 2013;424:99-103
[30] Tryndyak VP et al. Plasma microRNAs are sensitive indicators of inter-strain differences 
in the severity of liver injury induced in mice by a choline-and folate-deficient diet. 
Toxicology and Applied Pharmacology. 2012;262(1):52-59
[31] Gerhard GS, DiStefano JK. Micro RNAs in the development of non-alcoholic fatty liver 
disease. World Journal of Hepatology. 2015;7(2):226
[32] Ceccarelli S et al. Dual role of microRNAs in NAFLD. International Journal of Molecular 
Sciences. 2013;14(4):8437-8455
[33] Volinia S et al. A microRNA expression signature of human solid tumors defines cancer 
gene targets. Proceedings of the National Academy of Sciences of the United States of 
America. 2006;103(7):2257-2261
[34] Tomimaru Y et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-
α/5-fluorouracil in hepatocellular carcinoma cells. British Journal of Cancer. 2010;103(10): 
1617
[35] Karakatsanis A et al. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, 
miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular car-
cinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Molecular 
Carcinogenesis. 2013;52(4):297-303
[36] Gramantieri L et al. MicroRNA involvement in hepatocellular carcinoma. Journal of 
Cellular and Molecular Medicine. 2008;12(6a):2189-2204
[37] Hu S et al. MicroRNA-21 promotes cell proliferation in human hepatocellular carcinoma 
partly by targeting HEPN1. Tumor Biology. 2015;36(7):5467-5472
[38] Bao L et al. MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepa-
tocellular carcinoma progression through AKT/ERK pathways. Cancer Letters. 2013;337 
(2):226-236
[39] Zhang Z et al. microRNA-146a inhibits cancer metastasis by downregulating VEGF 
through dual pathways in hepatocellular carcinoma. Molecular Cancer. 2015;14(1):5
[40] Rong M et al. Expression and clinicopathological significance of miR-146a in hepatocel-
lular carcinoma tissues. Upsala Journal of Medical Sciences. 2014;119(1):19-24
[41] Murakami Y et al. Comprehensive analysis of microRNA expression patterns in hepato-
cellular carcinoma and non-tumorous tissues. Oncogene. 2006;25(17):2537
Hepatitis C - From Infection to Cure100
[42] Pineau P et al. miR-221 overexpression contributes to liver tumorigenesis. Proceedings 
of the National Academy of Sciences. 2010;107(1):264-269
[43] Fornari F et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human 
hepatocellular carcinoma. Oncogene. 2008;27(43):5651
[44] Gramantieri L et al. MicroRNA-221 targets Bmf in hepatocellular carcinoma and corre-
lates with tumor multifocality. Clinical Cancer Research. 2009;15(16):5073-5081
[45] Bae HJ et al. MicroRNA-221 governs tumor suppressor HDAC6 to potentiate malignant 
progression of liver cancer. Journal of Hepatology. 2015;63(2):408-419
[46] Morishita A, Masaki T. miRNA in hepatocellular carcinoma. Hepatology Research. 
2015;45(2):128-141
[47] Jopling C. Liver-specific microRNA-122: Biogenesis and function. RNA Biology. 2012; 
9(2):137-142
[48] Wang B et al. Reciprocal regulation of microRNA-122 and c-Myc in hepatocellular can-
cer: Role of E2F1 and transcription factor dimerization partner 2. Hepatology. 2014; 
59(2):555-566
[49] Coulouarn C et al. Loss of miR-122 expression in liver cancer correlates with suppression 
of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009;28(40):3526
[50] Zoni E et al. Epithelial plasticity in cancer: Unmasking a MicroRNA network for TGF-β-, 
Notch-, and Wnt-mediated EMT. Journal of Oncology. 2015;2015
[51] Liu S et al. MicroRNA-135a contributes to the development of portal vein tumor throm-
bus by promoting metastasis in hepatocellular carcinoma. Journal of Hepatology. 2012; 
56(2):389-396
[52] Kota SK, Balasubramanian S. Cancer therapy via modulation of micro RNA levels: A 
promising future. Drug Discovery Today. 2010;15(17-18):733-740
Micro-RNA in Hepatocellular Carcinoma - Related Hepatitis C Virus Patients in Correlation…
http://dx.doi.org/10.5772/intechopen.76209
101

